Author Details

Scroll

Refine your search

Collections

Medical Collection

Co-Authors

Journals

Asian Journal of Pharmaceutical Research and Health Care

Year

2018
2019

Authors

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

Le, Thuy Ai Huyen

miRNA-141 as the Biomarker for Human Cancers

Abstract Views :281 | PDF Views:176

Authors

Thuan Duc Lao ¹, Phuong Kim Truong ², Thuy Ai Huyen Le ²

Affiliations
1 University of Science, Vietnam National University, Ho Chi Minh City, VN
2 Department of Pharmaceutical and Medical Biotechnology, Faculty of Biotechnology, Ho Chi Minh City Open University, Ho Chi Minh City, VN

Source

Asian Journal of Pharmaceutical Research and Health Care, Vol 10, No 2 (2018), Pagination: 42-49

Abstract

microRNA (miRNA) is considered to be a pivotal role in human numerous biological process, and their abnormal expression that functions either as tumor suppressor or oncogenes results in human cancer initiation and development microRNA-141 (miR-141), belonged to the miR-200 family, located at 12p13.31 and is also found to be abundantly expressed in many human cancers. Additionally, Prognostic and predictive miR-141 signatures have been defined for a variety of cancer types. This review summarized the biogenesis and processing of miRNA, as well as the roles of miR-141 in human cancer pathways, its targets and the potential utility of miR-141 as prognostic biomarkers.

Keywords

Biomarker, Human Cancer, microRNA, microRNA-141.

Full Text

References

Croce CM, Calin GA. miRNAs, cancer, and stem cell division. Cell. 2005; 122(1):6–7. Crossref PMid:16009126

Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993; 75(5):843–54. Crossref

Ha M, Kim VN. Regulation of microRNA biogenesis. Nat Rev Mol Cell Biol. 2014; 15(8):509–24. Crossref PMid:25027649

Filipowicz W, Bhattacharyya SN, Sonenberg N. Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet. 2008; 9(2):102–14. Crossref PMid:18197166

Liu Y, Zhao R, Wang H, Luo Y, Wang X, Niu W, et al. miR-141 is involved in BRD7-mediated cell proliferation and tumor formation through suppression of the PTEN/AKT pathway in nasopharyngeal carcinoma. Cell Death Dis. 2016; 24(7):e2156. Crossref PMid:27010857 PMCid:PMC4823963

Bushati N, Cohen SM. microRNA functions. Annu Rev Cell Dev Biol. 2007; 23:175–205. Crossref PMid:17506695

Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006; 6(11):857–66. Crossref PMid:17060945

Iorio MV, Croce CM. MicroRNAs in cancer: small molecules with a huge impact. J Clin Oncol. 2009; 27(34):5848–56. Crossref PMid:19884536 PMCid:PMC2793003

Spence T, Bruce J, Yip KW, Liu FF. MicroRNAs in nasopharyngeal carcinoma. Chin Clin Oncol. 2016; 5(2):17. Crossref PMid:27121877

Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116(2):281–97. Crossref

Macfarlane LA, Murphy PR. MicroRNA: Biogenesis, function and role in cancer. Curr Genomics. 2010; 11(7):537–61. Crossref PMid:21532838 PMCid:PMC3048316

Lin SL, Kim H, Ying SY. Intron-mediated RNA interference and microRNA (miRNA). Front Biosci. 2008; 13:2216–30. Crossref PMid:17981704

Cai X, Hagedorn CH, Cullen BR. Human microRNAs are processed from capped, polyadenylated transcripts that can also function as mRNAs. RNA. 2004; 10(12):1957–66. Crossref PMid:15525708 PMCid:PMC1370684

Lee Y, Kim M, Han J, Yeom KH, Lee S, Baek SH, Kim VN. MicroRNA genes are transcribed by RNA polymerase II. EMBO J. 2004; 23(20):4051–60. Crossref PMid:15372072 PMCid:PMC524334

Kim VN, Han J, Siomi MC. Biogenesis of small RNAs in animals. Nat Rev Mol Cell Biol. 2009; 10(2):126–39. Crossref PMid:19165215

Lee Y, Ahn C, Han J, Choi H, Kim J, Yim J, et al. The nuclear RNase III Drosha initiates microRNA processing. Nature. 2003; 425(6956):415–9. Crossref PMid:14508493

Yi R, Qin Y, Macara IG, Cullen BR. Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs. Genes and Development. 2003; 17(24):3011–6. Crossref PMid:14681208 PMCid:PMC305252

Inui M, Martello G, Piccolo S. MicroRNA control of signal transduction. Nat Rev Mol Cell Biol. 2010; 11(4):252–63. Crossref PMid:20216554

Shenouda SK, Alahari SK. MicroRNA function in cancer: oncogene or a tumor suppressor? Cancer Metastasis Rev. 2009; 28(3-4):369–78. Crossref PMid:20012925

Zhang L, Deng T, Li X, Liu H, Zhou H, Ma J, et al. microRNA-141 is involved in a nasopharyngeal carcinomarelated genes network. Carcinogenesis. 2010; 31(4):559–66. Crossref PMid:20053927

Liu Y, Ding Y, Huang J, Wang S, Ni W, Guan J, et al. MiR141 suppresses the migration and invasion of HCC cells by targeting Tiam1. PLoS One. 2014; 9(2):e88393. Crossref PMid:24551096 PMCid:PMC3923786

Wu SM, Ai HW, Zhang DY, Han XQ, Pan Q, Luo FL, et al. MiR-141 targets ZEB2 to suppress HCC progression. Tumour Biol. 2014; 35(10):9993–7. Crossref PMid:25008569

Lin L, Liang H, Wang Y, Yin X, Hu Y, Huang J, et al. microRNA-141 inhibits cell proliferation and invasion and promotes apoptosis by targeting hepatocyte nuclear factor-3β in hepatocellular carcinoma cells. BMC Cancer. 2014; 14:879. Crossref PMid:25425543 PMCid:PMC4289273

Hu M, Xia M, Chen X, Lin Z, Xu Y, Ma Y, et al. MicroRNA-141 regulates Smad interacting protein 1 (SIP1) and inhibits migration and invasion of colorectal cancer cells. Dig Dis Sci. 2010; 55(8):2365–72. Crossref PMid:19830559

Ding L, Yu LL, Han N, Zhang BT. miR-141 promotes colon cancer cell proliferation by inhibiting MAP2K4. Oncol Lett. 2017; 13(3):1665–71. Crossref PMid:28454307 PMCid:PMC5403415

Li JZ, Li J, Wang HQ, Li X, Wen B, Wang YJ. MiR-141-3p promotes prostate cancer cell proliferation through inhibiting kruppel-like factor-9 expression. Biochem Biophys Res Commun. 2017; 482(4):1381–6. Crossref PMid:27956179

Brase JC, Johannes M, Schlomm T, Fälth M, Haese A, Steuber T, et al. Circulating miRNAs are correlated with tumor progression in prostate cancer. Int J Cancer. 2011; 128(3):608–16. Crossref PMid:20473869

Xiao J, Gong AY, Eischeid AN, Chen D, Deng C, Young CY, et al. miR-141 modulates androgen receptor transcriptional activity in human prostate cancer cells through targeting the small heterodimer partner protein. Prostate. 2012; 72(14):1514–22. Crossref PMid:22314666

Wang XL, Xie HY, Zhu CD, Zhu XF, Cao GX, Chen XH, et al. Increased miR-141 expression is associated with diagnosis and favorable prognosis of patients with bladder cancer. Tumour Biol. 2015; 36(2):877–83. Crossref PMid:25304156

Mahdavinezhad A, Mousavi-Bahar SH, Poorolajal J, Yadegarazari R, Jafari M, Shabab N, et al. Evaluation of miR141, miR-200c, miR-30b expression and clinicopathological features of bladder cancer. Int J Mol Cell Med. 2015; 4(1):32–9. PMid:25815280 PMCid:PMC4359703

van Jaarsveld MT, Helleman J, Boersma AW, van Kuijk PF, van Ijcken WF, Despierre E, et al. miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells. Oncogene. 2013; 32(36):4284–93. Crossref PMid:23045278

Chen JL, Chen F, Zhang TT, Liu NF. Suppression of SIK1 by miR-141 in human ovarian cancer cell lines and tissues. Int J Mol Med. 2016; 37(6):1601–10. Crossref PMid:27081781

Mateescu B, Batista L, Cardon M, Gruosso T, de Feraudy Y, Mariani O, et al. miR-141 and miR-200a act on ovarian tumorigenesis by controlling oxidative stress response. Nat Med. 2011; 17(12):1627–35. Crossref PMid:22101765

Li P, Xu T, Zhou X, Liao L, Pang G, Luo W, et al. Downregulation of miRNA-141 in breast cancer cells is associated with cell migration and invasion: Involvement of ANP32E targeting. Cancer Med. 2017; 6(3):662–72. Crossref PMid:28220627 PMCid:PMC5345683

Choi SK, Kim HS, Jin T, Hwang EH, Jung M, Moon WK. Overexpression of the miR-141/200c cluster promotes the migratory and invasive ability of triple-negative breast cancer cells through the activation of the FAK and PI3K/AKT signaling pathways by secreting VEGF-A. BMC Cancer. 2016; 16:570. Crossref PMid:27484639 PMCid:PMC4969651

Finlay-Schultz J, Cittelly DM, Hendricks P, Patel P, Kabos P, Jacobsen BM, et al. Progesterone downregulation of miR141 contributes to expansion of stem-like breast cancer cells through maintenance of progesterone receptor and Stat5a. Oncogene. 2015; 34(28):3676–87. Crossref PMid:25241899 PMCid:PMC4369481

Vandewalle C, Comijn J, De Craene B, Vermassen P, Bruyneel E, Andersen H, et al. SIP1/ZEB2 induces EMT by repressing genes of different epithelial cell–cell junctions. Nucleic Acids Research. 2005; 33(20):6566–78. Crossref PMid:16314317 PMCid:PMC1298926

Tang K, Xu H. Prognostic value of meta-signature miRNAs in renal cell carcinoma: An integrated miRNA expression profiling analysis. Scientific Reports. 2015; 5:10272. Crossref PMid:25974855 PMCid:PMC4431463

Chen X, Wang X, Ruan A, Han W, Zhao Y, Lu X, et al. miR-141 is a key regulator of renal cell carcinoma proliferation and metastasis by controlling EphA2 expression. Clin Cancer Res. 2014; 20(10):2617–30. Crossref PMid:24647573

Walworth NC. Cell-cycle checkpoint kinases: Checking in on the cell cycle. Curr Opin Cell Biol. 2000; 12(6):697–704. Crossref

Tricoli JV, Jacobson JW. MicroRNA: Potential for cancer detection, diagnosis, and prognosis. Cancer Res. 2007; 67(10):4553–5. Crossref PMid:17510380

Macha MA, Seshacharyulu P, Krishn SR, Pai P, Rachagani S, Jain M, et al. MicroRNAs (miRNAs) as biomarker(s) for prognosis and diagnosis of gastrointestinal (GI) cancers. Curr Pharm Des.2014; 20(33):5287–97. Crossref PMid:24479799 PMCid:PMC4113605

Fendler A, Stephan C, Yousef GM, Kristiansen G, Jung K. The translational potential of microRNAs as biofluid markers of urological tumours. Nat Rev Urol. 2016; 13(12):734–52. Crossref PMid:27804986

Valadi H, Ekström K, Bossios A, Sjöstrand M, Lee JJ, Lötvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 2007; 9(6):654–9. Crossref PMid:17486113

Zheng H, Liu JY, Song FJ, Chen KX. Advances in circulating microRNAs as diagnostic and prognostic markers for ovarian cancer. Cancer Biology and Medicine. 2013; 10(3):123–30. PMid:24379986 PMCid:PMC3860338

Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A. 2008; 105(30):10513–8. Crossref PMid:18663219 PMCid:PMC2492472

Gonzales JC, Fink LM, Goodman OB Jr, Symanowski JT, Vogelzang NJ, Ward DC. Comparison of circulating MicroRNA 141 to circulating tumor cells, lactate dehydrogenase, and prostate-specific antigen for determining treatment response in patients with metastatic prostate cancer. Clin Genitourin Cancer. 2011; 9(1):39–45. Crossref PMid:21723797

Antolín S, Calvo L, Blanco-Calvo M, Santiago MP, LorenzoPati-o MJ, Haz-Conde M, et al. Circulating miR-200c and miR-141 and outcomes in patients with breast cancer. BMC Cancer. 2015; 15:297. Crossref PMid:25885099 PMCid:PMC4405843

Cheng H, Zhang L, Cogdell DE, Zheng H, Schetter AJ, Nykter M, et al. Circulating plasma MiR-141 is a novel biomarker for metastatic colon cancer and predicts poor prognosis. PLoS One. 2011; 6(3):e17745. Crossref PMid:21445232 PMCid:PMC3060165

Characteristic of ZMYND10 Gene’s Promoter Hypermethylation in Nasopharyngeal Carcinoma Biopsies from Vietnamese Patients

Abstract Views :240 | PDF Views:130

Authors

Thuan Duc Lao ¹, Thuy Ai Huyen Le ²

Affiliations
1 University of Science, Vietnam National University, Ho Chi Minh City, VN
2 Department of Pharmaceutical and Medical Biotechnology, Ho Chi Minh City Open University, Ho Chi Minh City, VN

Source

Asian Journal of Pharmaceutical Research and Health Care, Vol 10, No 3 (2018), Pagination: 69-74

Abstract

Silencing of tumor suppressor gene, which caused by the DNA hypermethylation, an epigenetic modification, has been reported to be involved in human various cancers, including nasopharyngeal carcinoma. The aims of this study were to identify and evaluate the hypermethylation frequency of the ZMYND10 promoter, which located at 3p21.3, in nasopharyngeal biopsies from Vietnamese patients by Nested Methylation Specific PCR (Nested MSP). In current study, ninety tumor biopsies and ninety healthy samples, which were obtained from Cho Ray hospital, were enrolled into study. As the results, the hypermethylation frequency of ZMYND10 gene promoter was more frequent in tumor biopsies. In detail, the hypermethylation frequency of ZMYND10 gene promoter were 81.11% (73 of 90 samples), and 45.56% (41 of 90 samples) for in NPC biopsies and non-cancerous specimens. A trend toward positive association was found between hypermethylation of ZMYND10 gene and nasopharyngeal carcinoma (p < 0.0007). Additionally, the high Odds ratio (OR) and Relative risk were observed (OR = 5.13, RR = 2.49) (p <0.0001). In conclusion, our data suggested that the hypermethylation of ZMYND10 gene promoter is a significant in nasopharyngeal carcinoma in Vietnamese patients.

Keywords

Hypermethylation, Nasopharyngeal Carcinoma, Tumor Suppressor Gene, ZMYND10.

Full Text

References

Sham JS, Wei WI, Zong YS, Choy D, Guo YQ, Luo Y, Lin ZX, Ng MH, et al. Detection of subclinical nasopharyngeal carcinoma by fibreoptic endoscopy and multiple biopsy. Lancet. 1990; 335(8686):371–4. https:// doi.org/10.1016/0140-6736(90)90206-K

Chang ET, Adami HO. The enigmatic epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev. 2006; 15(10):1765–77. https://doi.org/10.1158/10559965.EPI-06-0353 PMid:17035381

GLOBOCAN. Estimated cancer incidence, mortality and prevalence worldwide in 2012. Available from: http://globocan.iarc.fr/Pages/fact_sheets_population.aspx

Hildesheim A, Levine PH. Etiology of nasopharyngeal carcinoma: A review. Epidemiol Rev. 1993; 15(2):466–85. https://doi.org/10.1093/oxfordjournals.epirev.a036130 PMid:8174667

Herman JG, Graff JR, Myöhänen S, Nelkin BD, Baylin SB. Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A. 1996; 93(18):9821–6. https://doi.org/10.1073/pnas.93.18.9821 PMid:8790415 PMCid:PMC38513

Santini V, Kantarjian HM, Issa JP. Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications. Ann Intern Med. 2001; 134(7):573–86. https:// doi.org/10.7326/0003-4819-134-7-200104030-00011 PMid:11281740

Challouf S, Ziadi S, Zaghdoudi R, Ksiaa F, Ben Gacem R, Trimeche M. Patterns of aberrant DNA hypermethylation in nasopharyngeal carcinoma in Tunisian patients. Clin Chim Acta. 2012; 413(7-8):795–802. https://doi.org/10.1016/j.cca.2012.01.018 PMid:22296674

Kok K, Naylor SL, Buys CH. Deletions of the short arm of chromosome 3 in solid tumors and the search for suppressor genes. Adv Cancer Res. 1997; 71:27–92. https://doi.org/10.1016/S0065-230X(08)60096-2

Ji L, Minna JD, Roth JA. 3p21.3 tumor suppressor cluster: prospects for translational applications. Future Oncol. 2005; 1(1):79–92. https://doi.org/10.1517/14796694.1.1.79 PMid:16555978

Cheng Y, Ho RL, Chan KC, Kan R, Tung E, Lung HL, et al. Anti-angiogenic pathway associations of the 3p21.3 mapped BLU gene in nasopharyngeal carcinoma. Oncogene. 2015; 34(32):4219–28. https://doi.org/10.1038/onc.2014.353 PMid:25347745 PMCid:PMC4761643

Hesson LB, Cooper WN, Latif F. Evaluation of the 3p21.3 tumour-suppressor gene cluster. Oncogene. 2007; 26(52):7283–301. https://doi.org/10.1038/sj.onc.1210547 PMid:17533367

Liu XQ, Chen HK, Zhang XS, Pan ZG, Li A, Feng QS, et al. Alterations of BLU, a candidate tumor suppressor gene on chromosome 3p21.3, in human nasopharyngeal carcinoma. Int J Cancer. 2003; 106(1):60–5. https://doi.org/10.1002/ijc.11166 PMid:12794757

Qiu GH, Tan LK, Loh KS, Lim CY, Srivastava G, Tsai ST, et al. The candidate tumor suppressor gene BLU, located at the commonly deleted region 3p21.3, is an E2F-regulated, stress-responsive gene and inactivated by both epigenetic and genetic mechanisms in nasopharyngeal carcinoma. Oncogene. 2004; 23(27):4793–806. https://doi.org/10.1038/ sj.onc.1207632 PMid:15122337

Ayadi W, Karray-Hakim H, Khabir A, Feki L, Charfi S, Boudawara T, et al. Aberrant methylation of p16, DLEC1, BLU and E-cadherin gene promoters in nasopharyngeal carcinoma biopsies from Tunisian patients. Anticancer Res. 2008; 28(4B):2161–7. PMid:18751390

Epstein JB, Jones CK. Presenting signs and symptoms of nasopharyngeal carcinoma. Oral Surg Oral Med Oral Pathol. 1993; 75(1):32–6. https://doi.org/10.1016/0030-4220(93)90402-P

Hao SP, Tsang NM, Chang KP, Ueng SH. Molecular diagnosis of nasopharyngeal carcinoma: detecting LMP-1 and EBNA by nasopharyngeal swab. Otolaryngol Head Neck Surg. 2004; 131(5):651–4. https://doi.org/10.1016/j.otohns.2004.04.013 PMid:15523443

Lo KW, Huang DP. Genetic and epigenetic changes in nasopharyngeal carcinoma. Semin Cancer Biol. 2002; 12(6):451–62. https://doi.org/10.1016/ S1044579X02000883

Palmisano WA, Divine KK, Saccomanno G, Gilliland FD, Baylin SB, Herman JG, et al. Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res. 2000; 60(21):5954–8. PMid:11085511

Zhang X, Liu H, Li B, uang P, Shao J, He Z. Tumor suppressor BLU inhibits proliferation of nasopharyngeal carcinoma cells by regulation of cell cycle, c-Jun N-terminal kinase and the cyclin D1 promoter. BMC Cancer. 2012; 12:267. https://doi.org/10.1186/1471-2407-12-267 PMid:22727408 PMCid:PMC3585814

Study of Mir-141 and its Potential Targeted mRNA PTEN Expression in Nasopharyngeal Carcinoma:From in Silico to Initial Experiment Analysis

Abstract Views :189 | PDF Views:138

Authors

Duc Thuan Lao ¹, Danh Hoang Nguyen ², Thuy Ai Huyen Le ²

Affiliations
1 University of Science, Vietnam National University Ho Chi Minh City, VN
2 Ho Chi Minh City Open University, Ho Chi Minh City, VN

Source

Asian Journal of Pharmaceutical Research and Health Care, Vol 10, No 3 (2018), Pagination: 75-83

Abstract

Recently, accumulating evidences indicated that microRNA-141 (miR-141) is associated with NPC due to their abilities to affect the expression of genes that modulate tumorigenesis. Unfortunately, there is still limited publication about miR-141 expression in Vietnamese nasopharyngeal cancer patients. In this study, we adopted bioinformatics tools, such as Pictar, Target Scan, miRDB, etc. to predict its target gene. As the results, PTEN (phosphatase and tensin homolog gene), acts oncogenic role associated with biological processes lead to the nasopharyngeal carcinogenesis, was identified as the direct target of miR-141. Experimentally, we reported the evaluation of miR-141 and PTEN expression in NPC biopsy samples and non-cancerous swab samples. The present study demonstrated that miR-141 was upregulated 9.38 times, and PTEN expression was significantly lowered in NPC biopsy samples compared to non-cancerous epithelial swab samples. Our finding demonstrated that the miR-141 was upregulated and PTEN was down regulated in NPC biopsy samples. In the upcoming research, a larger clinical sample size from patients at each stage of the NPC will be performed to understand the expression pattern of the miR-141 and PTEN for further applied in early diagnosis and prognosis as well as therapeutic of NPC.

Keywords

miR-141, Nasopharyngeal Carcinoma, PTEN.

Full Text

References

GLOBOCAN. Estimated cancer incidence, mortality and prevalence worldwide in 2012; 2012. Available from: http://globocan.iarc.fr/Pages/fact_sheets_population.aspx

Mahdavifar N, Ghoncheh M, Mohammadian-Hafshejani A, Khosravi B, Salehiniya H. Epidemiology and inequality in the incidence and mortality of Nasopharynx cancer in Asia. Osong Public Health and Research Perspectives. 2016; 7(6):360–72. https://doi.org/10.1016/j.phrp.2016.11.002 PMid:28053841 PMCid:PMC5194228

Croce CM, Calin GA. miRNAs, cancer, and stem cell division. Cell. 2005; 122(1):6–7. https://doi.org/10.1016/j.cell.2005.06.036 PMid:16009126

Bartel DP. MicroRNAs: Target recognition and regulatory functions. Cell. 2009; 136(2):215–33. https://doi.org/10.1016/j.cell.2009.01.002 PMid:19167326 PMCid:PMC3794896

He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet. 2004; 5(7):522–31. https://doi.org/10.1038/nrg1379 PMid:15211354

Bushati N, Cohen SM. microRNA functions. Annu Rev Cell Dev Biol. 2007; 23:175–205. https://doi.org/10.1146/ annurev.cellbio.23.090506.123406 PMid:17506695

Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006; 6(11):857–66. https://doi.org/10.1038/nrc1997 PMid:17060945

Ha M, Kim VN. Regulation of microRNA biogenesis. Nat Rev Mol Cell Biol. 2014; 15(8):509–24. https://doi.org/10.1038/nrm3838 PMid:25027649

Zhang B, Pan X, Cobb GP, Anderson TA. microRNAs as oncogenes and tumor suppressors. Dev Biol. 2007; 302(1):1–12. https://doi.org/10.1016/j.ydbio.2006.08.028

Hayes J, Peruzzi PP, Lawler S. MicroRNAs in cancer: Biomarkers, functions and therapy. Trends Mol Med. 2014; 20(8):460-9. https://doi.org/10.1016/j.molmed.2014.06.005 PMid:25027972

Kala R, Peek GW, Hardy TM, Tollefsbol TO. MicroRNAs: an emerging science in cancer epigenetics. J Clin Bioinforma. 2013; 3(1):6. https://doi.org/10.1186/2043-9113-3-6 PMid:23497588 PMCid:PMC3608239

Lee KT, Tan JK, Lam AK, Gan SY. MicroRNAs serving as potential biomarkers and therapeutic targets in nasopharyngeal carcinoma: A critical review. Crit Rev Oncol Hematol. 2016; 103:1–9. https://doi.org/10.1016/j.critrevonc.2016.04.006 PMid:27179594

Zhang L, Deng T, Li X, Liu H, Zhou H, Ma J, et al. microRNA-141 is involved in a nasopharyngeal carcinomarelated genes network. Carcinogenesis. 2010; 31(4):559–66. https://doi.org/10.1093/carcin/bgp335 PMid:20053927

Zuo QF, Zhang R, Li BS, Zhao YL, Zhuang Y, Yu T, et al. MicroRNA-141 inhibits tumor growth and metastasis in gastric cancer by directly targeting transcriptional co-activator with PDZ-binding motif, TAZ. Cell Death Dis. 2015; 6:e1623. https://doi.org/10.1038/cddis.2014.573

Liu Y, Zhao R, Wang H, Luo Y, Wang X, Niu W, et al. miR-141 is involved in BRD7-mediated cell proliferation and tumor formation through suppression of the PTEN/ AKT pathway in nasopharyngeal carcinoma. Cell Death Dis. 2016; 7:e2156. https://doi.org/10.1038/cddis.2016.64 PMid:27010857 PMCid:PMC4823963

Liu Y, Zhao R, Wei Y, Li M, Wang H, Niu W, et al. BRD7 expression and c-Myc activation forms a double-negative feedback loop that controls the cell proliferation and tumor growth of nasopharyngeal carcinoma by targeting oncogenic miR-141. J Exp Clin Cancer Res. 2018; 37(1):64. https://doi.org/10.1186/s13046-018-0734-2 PMid:29559001 PMCid:PMC5859396

Lao DT, Truong KP, Le HAT. miRNA-141 as the Biomarker for Human Cancers. AJPRHC. 2018; 10(2):42-9. https:// doi.org/10.18311/ajprhc/2018/21486

Sano T, Lin H, Chen X, Langford LA, Koul D, Bondy ML, et al. Differential expression of MMAC/PTEN in glioblastoma multiforme: relationship to localization and prognosis. Cancer Res. 1999; 59(8):1820–4. PMid:10213484

Li A, Zhang XS, Jiang JH, Wang HH, Liu XQ, Pan ZG, et al. Transcriptional expression of RPMS1 in nasopharyngeal carcinoma and its oncogenic potential. Cell Cycle. 2005; 4(2):304–9. https://doi.org/10.4161/cc.4.2.1416 PMid:15725729

Sun H, Lesche R, Li DM, Liliental J, Zhang H, Gao J, et al. PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3,4,5,-trisphosphate and Akt/protein kinase B signaling pathway. Proc Natl Acad Sci U S A. 1999; 96(11):6199–204. https://doi.org/10.1073/ pnas.96.11.6199 PMid:10339565 PMCid:PMC26859

Mahimainathan L, Choudhury GG. Inactivation of plateletderived growth factor receptor by the tumor suppressor PTEN provides a novel mechanism of action of the phosphatase. J Biol Chem. 2004; 279(15):15258–68. https:// doi.org/10.1074/jbc.M314328200 PMid:14718524

Shinde SR, Maddika S. PTEN modulates EGFR late endocytic trafficking and degradation by dephosphorylating Rab7. Nat Commun. 2016; 7:10689. https://doi.org/10.1038/ ncomms10689 PMid:26869029 PMCid:PMC4754336

Peng W, Chen JQ, Liu C, Malu S, Creasy C, Tetzlaff MT, et al. Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. Cancer Discov. 2016; 6(2):202–16. https:// doi.org/10.1158/2159-8290.CD-15-0283 PMid:26645196 PMCid:PMC4744499

Hill R, Wu H. PTEN, stem cells, and cancer stem cells. J Biol Chem. 2009; 284(18):11755–9. https://doi.org/10.1074/jbc.R800071200 PMid:19117948 PMCid:PMC2673242

Maier D, Jones G, Li X, Schönthal AH, Gratzl O, Van Meir EG, et al. The PTEN lipid phosphatase domain is not required to inhibit invasion of glioma cells. Cancer Res. 1999; 59(21):5479–82. PMid:10554022

Leslie NR, Yang X, Downes CP, Weijer CJ. PtdIns(3,4,5) P(3)-dependent and -independent roles for PTEN in the control of cell migration. Curr Biol. 2007; 17(2):115–25. https://doi.org/10.1016/j.cub.2006.12.026 PMid:17240336 PMCid:PMC1885949

Puc J, Parsons R. PTEN loss inhibits CHK1 to cause double stranded-DNA breaks in cells. Cell Cycle. 2005; 4(7):927–9. https://doi.org/10.4161/cc.4.7.1795 PMid:15970699

Shen WH, Balajee AS, Wang J, Wu H, Eng C, Pandolfi PP, et al. Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell. 2007; 128(1):157–70. https:// doi.org/10.1016/j.cell.2006.11.042 PMid:17218262

Li J, Simpson L, Takahashi M, Miliaresis C, Myers MP, Tonks N, et al. The PTEN/MMAC1 tumor suppressor induces cell death that is rescued by the AKT/protein kinase B oncogene. Cancer Res. 1998; 58(24):5667–72. PMid:9865719

Xu Z, Stokoe D, Kane LP, Weiss A. The inducible expression of the tumor suppressor gene PTEN promotes apoptosis and decreases cell size by inhibiting the PI3K/Akt pathway in Jurkat T cells. Cell Growth Differ. 2002; 13(7):285–96. PMid:12133897

Pal A, Barber TM, Van de Bunt M, Rudge SA, Zhang Q, Lachlan KL, et al. PTEN mutations as a cause of constitutive insulin sensitivity and obesity. N Engl J Med. 2012; 367(11):1002–11. https://doi.org/10.1056/ NEJMoa1113966 PMid:22970944 PMCid:PMC4072504

Ortega-Molina A, Serrano M. PTEN in cancer, metabolism, and aging. Trends Endocrinol Metab. 2013; 24(4):184–9. https://doi.org/10.1016/j.tem.2012.11.002 PMid:23245767 PMCid:PMC3836169

Markopoulos GS, Roupakia E, Tokamani M, Chavdoula E, Hatziapostolou M, Polytarchou C, et al. A step-by-step microRNA guide to cancer development and metastasis. Cell Oncol (Dordr). 2017; 40(4):303–39. https://doi.org/10.1007/s13402-017-0341-9 PMid:28748501

Chen P, Guo X, Zhou H, Zhang W, Zeng Z, Liao Q, et al. SPLUNC1 regulates cell progression and apoptosis through the miR-141-PTEN/p27 Pathway, but is hindered by LMP1. Samant R, editor. PLoS ONE. 2013; 8(3):e56929.

First Record of Identification of RPMS1 Gene Variations in Vietnamese Nasopharyngeal Carcinoma Patients

Abstract Views :256 | PDF Views:196

Authors

Duc Thuan Lao ¹, Danh Hoang Nguyen ¹, Minh Trong Quang ¹, Hue Hong Thieu ², Thuy Ai Huyen Le ¹

Affiliations
1 Ho Chi Minh City Open University, 97 Vo Van Tan Str., Ward 6, District 3 Ho Chi Minh City − 700000, VN
2 University of Science, Vietnam National University, Ho Chi Minh City, 227 Nguyen Van Cu Str., Ward 4, District 5 − 700000, VN

Source

Asian Journal of Pharmaceutical Research and Health Care, Vol 10, No 4 (2018), Pagination: 97-103

Abstract

Epstein-Barr Virus (EBV) infection and EBV genes’ variation are considered as the etiological factors contributed to Naso- Pharyngeal Carcinoma (NPC). In the latent EBV stage, not only the latent membrane proteins but also RPMS1 expression has been confirmed in all EBV-associated tumors. In Vietnam, an Asian country with the high incidence, mortality rate of NPC, had limit research on the RMPS1 gene variation. Therefore, the objects of current study were to identify the pattern of RMPS1 variations in Vietnamese NPC patients for its value further applied in NPC patients. In this study, thirty NPC biopsy samples and thirty non-cancerous swab specimens were collected from local patients, analyzed by PCR, sequencing and compared to previous B95-8 sequence. As the results, the strongly association between the detection of RPSM1 gene and NPC incidence in Vietnamese NPC patients was determined. Additionally, the RMPS1 gene variants, including wild-type, RMPS1-B, RMPS1-C, RMPS1-C*, were identified. Among them, RMPS1-C/C* was preferential in Vietnamese nasopharyngeal cancer. In conclusion, those data is the first dataset on the polymorphism in the RPMS1 gene in Vietnamese NPC patients, and could be utilized as a promising biomarker for prognosis, diagnosis and therapy for NPC based on the EBV gene variations.

Keywords

Nasopharyngeal Carcinoma, RPMS1, Variations.

Full Text

References

Sham JS, Wei WI, Zong YS, Choy D, Guo YQ, Luo Y, et al. Detection of subclinical nasopharyngeal carcinoma by fibreoptic endoscopy and multiple biopsy. Lancet. 1990; 335(8686):371−4. https://doi.org/10.1016/0140-6736(90)90206-K.

Chang ET, Adami HO. The enigmatic epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev. 2006; 15(10):1765−77. https://doi.org/10.1158/1055-9965.EPI-06-0353. PMid:17035381.

GLOBOCAN. Estimated cancer incidence, mortality and prevalence worldwide in 2012. Available from: http://globocan.iarc.fr/Pages/fact_sheets_population.aspx.

Tsao SW, Yip YL, Tsang CM, Pang PS, Lau VM, Zhang G, et al. Etiological factors of nasopharyngeal carcinoma. Oral Oncol. 2014; 50(5):330−38. https://doi.org/10.1016/j.oraloncology.2014.02.006. PMid: 24630258.

Lao TD, Truong PK, Le THA. miRNA-141 as the Biomarker for Human Cancers. AJPRHC. 2018; 10(2):42−49. https://doi.org/10.18311/ajprhc/2018/21486.

Lao TD, Nguyen DH, Le THA. Study of mir-141 and its Potential Targeted mRNA PTEN Expression in Nasopharyngeal Carcinoma: From in Silico to Initial Experiment Analysis. AJPRHC. 2018; 10(3):66−74. https://doi.org/10.18311/ajprhc/2018/22341.

Lao TD, Nguyen TV, Nguyen DH, Nguyen MT, Nguyen CH, Le THA. miR-141 is up-regulated in biopsies from Vietnamese patients with nasopharyngeal carcinoma. Braz Oral Res. 2018; 32:e126. https://doi.org/10.1590/18073107bor-2018.vol32.0126.

Hildesheim A, Levine PH. Etiology of nasopharyngeal carcinoma: a review. Epidemiol Rev. 1993; 15(2):466−85. https://doi.org/10.1093/oxfordjournals.epirev.a036130. PMid: 8174667.

Wu S, Liu W, Li H, Zhao Z, Yang Y, Xiao H, et al. Conservation and polymorphism of EBV RPMS1 gene in EBV-associated tumors and healthy individuals from endemic and non-endemic nasopharyngeal carcinoma areas in China. Virus Res. 2018; 250:75−80. https://doi.org/10.1016/j.virusres.2018.04.009. PMid: 29665370.

Young LS, Dawson CW, Eliopoulos AG. The expression and function of Epstein-Barr virus encoded latent genes. Molecular Pathology. 2000; 53(5):238−47. https://doi.org/10.1136/mp.53.5.238. PMid:11091847, PMCid: PMC1186976.

Marquitz AR, Raab-Traub N. The role of miRNAs and EBV BARTs in NPC. Semin Cancer Biol. 2012; 22(2):166−72. https://doi.org/10.1016/j.semcancer.2011.12.001. PMid: 22178394, PMCid: PMC3340885.

Gilligan KJ, Rajadurai P, Lin JC, Busson P, Abdel-Hamid M, Prasad U, et al. Expression of the Epstein-Barr virus BamHI A fragment in nasopharyngeal carcinoma: evidence for a viral protein expressed in vivo. J Virol. 1991; 65(11):6252−59.

Smith PR, de Jesus O, Turner D, Hollyoake M, Karstegl CE, Griffin BE, Karran L, Wang Y, Hayward SD, Farrell PJ. Structure and coding content of CST (BART) family RNAs of Epstein-Barr virus. J. Virol. 2000; 74(7):3082−92. https://doi.org/10.1128/JVI.74.7.3082-3092.2000. PMid: 10708423, PMCid: PMC111807.

Hui KF, Chan TF, Yang W, Shen JJ, Lam KP, Kwok H, Sham PC, Tsao SW, Kwong DL, Lung ML, Chiang AKS. High risk Epstein-Barr virus variants characterized by distinct polymorphisms in the EBER locus are strongly associated with nasopharyngeal carcinoma. Int. J. Cancer. 2018; [Epub ahead of print]. https://doi.org/10.1002/ijc.32049.

Chao M, Wang HN, Lu YJ, Chang YS, Yu JS. The V-val subtype Epstein-Barr virus nuclear antigen 1 promotes cell survival after serum withdrawal. Oncol Rep. 2015; 33(2):958−66. https://doi.org/10.3892/or.2014.3625. PMid: 25434292.

Feng FT, Cui Q, Liu WS, Guo YM, Feng QS, Chen LZ, Xu M, Luo B, Li DJ, Hu LF, Middeldorp JM, Ramayanti O, Tao Q, Cao SM, Jia WH, Bei JX, Zeng YX. A single nucleotide polymorphism in the Epstein-Barr virus genome is strongly associated with a high risk of nasopharyngeal carcinoma. Chin. J. Cancer. 2015; 34(12):563−72. https://doi.org/10.1186/s40880-015-0073-z.

Lao TD, Nguyen DH, Nguyen TM, Le TAH. Molecular Screening for Epstein-Barr virus (EBV): Detection of Genomic EBNA-1, EBNA-2, LMP-1, LMP-2 Among Vietnamese Patients with Nasopharyngeal Brush Samples. Asian Pac. J. Cancer Prev. 2017; 18(6):1675−1679.

Cui Q, Feng FT, Xu M, Liu WS, Yao YY, Xie SH, Li XZ, Ye ZL, Feng QS, Chen LZ, Bei JX, Feng L, Huang QH, Jia WH, Cao SM, Chang ET, Ye W, Adami HO, Zeng YX. Nasopharyngeal carcinoma risk prediction via salivary detection of host and Epstein-Barr virus genetic variants. Oncotarget. 2016; 8(56):95066−74. https://doi.org/10.18632/oncotarget.11144.

Yap YY, Hassan S, Chan M, Choo PK, Ravichandran M. Epstein-Barr virus DNA detection in the diagnosis of nasopharyngeal carcinoma. Otolaryngol Head Neck Surg. 2007; 136(6):986−91. https://doi.org/10.1016/j.otohns.2006.11.027. PMid: 17547993.

Zhang J, Chen H, Weinmaster G, Hayward SD. EpsteinBarr virus BamHi-a rightward transcript-encoded RPMS protein interacts with the CBF1-associated corepressor CIR to negatively regulate the activity of EBNA2 and NotchIC. J. Virol. 2001; 75(6):2946−56. https://doi.org/10.1128/JVI.75.6.2946-2956.2001. PMid: 11222720, PMCid: PMC115921.

Development of Stem-Loop Real-Time PCR Technique for miRNA-141 Expression Analysis in Nasopharyngeal Carcinoma

Abstract Views :206 | PDF Views:180

Authors

Thuan Duc Lao ¹, Thuy Ai Huyen Le ¹

Affiliations
1 Faculty of Biotechnology, Department of Pharmaceutical and Medical Biotechnology, Ho Chi Minh City Open University, Ward Co Giang, District 1, HCMC, Ho Chi Minh City, VN

Source

Asian Journal of Pharmaceutical Research and Health Care, Vol 11, No 2-4 (2019), Pagination: 30-36

Abstract

Background: The deregulation of miRNA-141 (miR-141) has been reported to be involved in development and progression of many various types of human cancers. Previously, it has been demonstrated that miR-141 served as the oncogenic role in nasopharyngeal carcinoma in different countries. However, in Vietnam, to our knowledge, there are limit study of the types of evaluation of miR-141 expression. Objective: For the aims to find out the novel diagnosis strategies and promising therapies for many human based on the expression of miRNA, we the stem-loop qRT-PCR method described here is to detect mature miRNA-141 in a fast, specific, accurate, and reliable manner. Methods: StL-miR-141, known as stem-loop RT primer is applied for Reversed transcriptase assay, followed by Real-time PCR assay using StL-F, STL-R primer and SYBR-Green. Results: Experimentally, this method was applied in detection of miR-141 in Vietnamese NPC biopsy samples, as the results, 5 of six NPC were positive to miR-141 expression. Moreover, the electrophoresis analysis was performed to evaluate the Specificity. The assay has shown high specific for miR-141 detection. Conclusion: We successfully designed the stem-loop RT primer, StL-F, STL-R primer, might be used as a rapid, simple method for the detectionwith a wider scope to apply this method onto the Vietnamese population.

Keywords

miRNAs, miR-141, Stem-Loop RT PCR.

Full Text

References

GLOBOCAN. Estimated cancer incidence, mortality and prevalence worldwide in 2012. 2012. http://globocan.iarc.fr/Pages/fact_sheets_population.aspx.

Mahdavifar N, Ghoncheh M, Mohammadian-Hafshejani A, Khosravi B, Salehiniya H. Epidemiology and inequality in the incidence and mortality of nasopharynx cancer in Asia. Osong Public Health Res. Perspect. 2016; 7(6):360-72. https://doi.org/10.1016/j.phrp.2016.11.002. PMid: 28053841, PMCid: PMC5194228.

Epstein JB, Jones CK. Presenting signs and symptoms of nasopharyngeal carcinoma. Oral Surg. Oral. Med. Oral. Pathol. 1993; 75(1):32-36. https://doi.org/10.1016/00304220(93)90402-P.

Hao SP, Tsang NM, Chang KP, Ueng SH. Molecular diagnosis of nasopharyngeal carcinoma: Detecting LMP-1 and EBNA by nasopharyngeal swab. Otolaryngol Head Neck Surg. 2004; 131(5):651-54. https://doi.org/10.1016/j.otohns.2004.04.013. PMid: 15523443.

Liu Y, Zhao R, Wang H, Luo Y, Wang X, Niu W, et al. miR-141 is involved in BRD7-mediated cell proliferation and tumor formation through suppression of the PTEN/AKT pathway in nasopharyngeal carcinoma. Cell Death Dis. 2016; 7:e2156. https://doi.org/10.1038/cddis.2016.64. PMid: 27010857, PMCid: PMC4823963.

Lee RC, Feinbaum RL, Ambros V. The C. elegansheterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993; 75(5):843-54. https://doi.org/10.1016/0092-8674(93)90529-Y.

Ha M, Kim VN. Regulation of microRNA biogenesis. Nat. Rev. Mol. Cell. Biol. 2014; 15(8):509-24. https://doi.org/10.1038/nrm3838. PMid: 25027649.

Bartel DP. MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 2004; 116(2):281-97. https://doi.org/10.1016/S0092-8674(04)00045-5.

Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat. Rev. Cancer. 2006; 6(11):857-66. https://doi.org/10.1038/nrc1997. PMid: 17060945.

Faraoni I, Antonetti FR, Cardone J, Bonmassar E. miR-155 gene: A typical multifunctional microRNA. Biochim. Biophys. Acta. Biochim. Biophys. Acta. 2009; 1792(6):497-505. https://doi.org/10.1016/j.bbadis.2009.02.013. PMid: 19268705.

Macfarlane LA, Murphy PR. Micro RNA: Biogenesis, function and role in cancer. Curr. Genomics. 2010; 11(7):537-61. https://doi.org/10.2174/138920210793175895. PMid: 21532838, PMCid: PMC3048316.

Du ZM, Hu LF, Wang HY, Yan LX, Zeng YX, Shao JY, et al. Upregulation of MiR-155 in nasopharyngeal carcinoma is partly driven by LMP1 and LMP2A and down regulates a negative prognostic marker JMJD1A. PLoS One. 2011; 6:e19137. https://doi.org/10.1371/journal.pone.0019137. PMid: 21541331, PMCid: PMC3082546.

Lovat F, Valeri N, Croce CM. MicroRNAs in the pathogenesis of cancer. Semin. Oncol. 2011; 38(6):724-33. https://doi.org/10.1053/j.seminoncol.2011.08.006. PMid: 22082758.

Amin M, Lam AK. Current perspectives of mi-RNA in oesophageal adenocarcinoma: Roles in predicting carcinogenesis, progression and values in clinical management. Exp. Mol. Pathol. 2015; 98(3):411-18. https://doi.org/10.1016/j.yexmp.2015.03.002. PMid: 25746664.

Lee KT, Tan JK, Lam AK, Gan SY. MicroRNAs serving as potential biomarkers and therapeutic targets in nasopharyngeal carcinoma: A critical review. Crit. Rev. Oncol. Hematol. 2016; 103:1-9. https://doi.org/10.1016/j.critrevonc.2016.04.006. PMid:27179594.

Lao DT, Truong KP, Le HAT.miRNA-141 as the Biomarker for Human Cancers. JPRHC. 2018; 10:42-49. https://doi.org/10.18311/ajprhc/2018/21486.

Li G, Huang M, Cai Y, Ke Y, Yang Y, Sun X. miR 141 inhibits glioma vasculogenic mimicry by controlling EphA2 expression. Mol. Med. Rep. 2018(2); 18:1395-1404. https://doi.org/10.3892/ mmr.2018.9108.

Lin L, Liang H, Wang Y, Yin X, Hu Y, Huang J, et al. microRNA-141 inhibits cell proliferation and invasion and promotes apoptosis by targeting hepatocyte nuclear factor-3β in hepatocellular carcinoma cells. BMC cancer. 2014; 14:879. https://doi.org/10.1186/1471-2407-14-879. PMid: 25425543, PMCid: PMC4289273.

Croce CM, Calin GA. miRNAs, cancer, and stem cell division. Cell. 2005; 122:6-7. https://doi.org/10.1016/j.cell.2005.06.036. PMid: 16009126.

Chen C, Ridzon DA, Broomer AJ, Zhou Z, Lee DH, Nguyen JT, et al. Real-time quantification of microRNAs by stemloop RT-PCR. Nucleic Acids Res. 2005; 33(20):e179. https://doi.org/10.1093/nar/gni178. PMid: 16314309, PMCid: PMC1292995.

The Prognosis Value of CDH-1 Methylation-The Epigenetic Biomarker in Nasopharyngeal Carcinoma:Systematic Review and Meta-Analysis

Abstract Views :188 | PDF Views:168

Authors

Thuan Duc Lao ¹, Phuong Kim Truong ¹, Hue Hong Thieu ², Thuy Ai Huyen Le ¹

Affiliations
1 Faculty of Biotechnology, Department of Pharmaceutical and Medical Biotechnology, Ho Chi Minh City Open University, Ho Chi Minh City − 700000, VN
2 Faculty of Biology and Biotechnology, Ho Chi Minh City University of Science, Hồ Chí Minh − 700000, VN

Source

Asian Journal of Pharmaceutical Research and Health Care, Vol 11, No 2-4 (2019), Pagination: 68-74

Abstract

Background: The phenome of CDH-1 gene methylation has been reported to be associated with the nasopharyngeal tumorigenesis. Objective: Aiming to evaluate the association between the CDH-1 gene methylation and nasopharyngeal cancer, and its correlation could be used as an epigenetic biomarker for nasopharyngeal cancer risk based on meta-analysis. Materials and Methods: Relevant articles were identified by searching MEDLINE database. The frequency and Odds Ratio (OR) were applied to estimate the effect of CDH-1 methylation based on random-/fix-effects models. Results: Total of 12 studies, including 500 samples from NPC patients and 201 samples from non-cancerous samples, were enrolled in current study. Overall, the frequency of CDH-1 gene methylation were 48.50% and 3.09% in the case and control group, respectively. The association between the CDH-1 gene methylation and risk of NPC was also confirmed by calculating OR value of 15.33 (95% CI = 7.82-30.06), based on the fix-effects model. Additionally, the significant association was also found between the methylation of CDH-1 gene and subgroups. Conclusion: this meta-analysis provides scientific evidences to suggest the CDH-1 methylation was the potential biomarker for risk of NPC.

Keywords

CDH-1, Epigenetic Biomarker, Nasopharyngeal carcinoma, Meta-Analysis.

Full Text

References

Sham JS, Wei WI, Zong YS, Choy D, Guo YQ, Luo Y, et al. Detection of subclinical nasopharyngeal carcinoma by fibreoptic endoscopy and multiple biopsy. Lancet 1990; 335(8686):371-74. https://doi.org/10.1016/01406736(90)90206-K

Chang CM, Yu KJ, Mbulaiteye SM, Hildesheim A, Bhatia K. The extent of genetic diversity of Epstein-Barr virus and its geographic and disease patterns: A need for reappraisal. Virus Res. 2009; 143(2):209-21. https://doi.org/10.1016/j.virusres.2009.07.005. PMid: 19596032, PMCid: PMC2731007.

Mahdavifar N, Ghoncheh M, Mohammadian-Hafshejani A, Khosravi B, Salehiniya H. Epidemiology and inequality in the incidence and mortality of Nasopharynx Cancer in Asia. Osong. Public Health Res. Perspect. 2016; 7(6):360-72. https:// doi.org/10.1016/j.phrp.2016.11.002. PMid: 28053841, PMCid: PMC5194228.

Lao TD, Nguyen TV, Nguyen DH, Nguyen MT, Nguyen CH, Le THA. miR-141 is up-regulated in biopsies from Vietnamese patients with nasopharyngeal carcinoma. Braz. Oral. Res. 2018a; 32:e126. https://doi.org/10.1590/1807-3107bor-2018.vol32.0126. PMid: 30569973.

Lao TD, Nguyen DH, Le THA. Study of mir-141 and its potential targeted mRNA PTEN expression in Nasopharyngeal Carcinoma: From in Silico to initial experiment analysis. AJPRHC. 2018b; 10(3):66-74. https://doi.org/10.18311/ajprhc/2018/22341.

Lao TD, Le THA. Epidemiology, incidence and mortality of Nasopharynx Cancer in Southeast Asia: An update report. Adv. Life Sci. 2020; 7(2):86-90.

Wang LH, Wu CF, Rajasekaran N, Shin YK. Loss of tumor suppressor gene function in human cancer: An Overview. Cell Physiol. Biochem. 2018; 51(6):2647-93. https://doi.org/10.1159/000495956. PMid: 30562755.

Goodwin M, Yap AS. Classical cadherin adhesion molecules: Coordinating cell adhesion, signaling and the cytoskeleton. J. Mol. Histol. 2004; 35:839-44. https://doi.org/10.1007/s10735004-1833-2. PMid: 15609097.

Jeanes A, Gottardi CJ, Yap AS. Cadherins and cancer: How does cadherin dysfunction promote tumor progression? Oncogene. 2008; 27(55):6920-29. https://doi.org/10.1038/ onc.2008.343. PMid: 19029934, PMCid: PMC2745643.

Moher D, Liberati A, Tetzlaff J, Altman DG, Altman D, Antes G, et al. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med. 2009; 6(7):e1000097. https://doi.org/10.1371/journal.pmed.1000097. PMid: 19621072, PMCid: PMC2707599.

Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat. Med. 2002; 21(11):1539-58. https://doi.org/10.1002/sim.1186. PMid: 12111919.

DerSimonian R. Meta-analysis in the design and monitoring of clinical trials. Stat. Med. 1996; 15(12):1237-48. https://doi.org/10.1002/(SICI)1097-0258(19960630)15:12<1237::AIDSIM301> 3.0.CO;2-N.

Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003; 327(7414):557-60.https://doi.org/10.1136/bmj.327.7414.557 PMid: 12958120, PMCid: PMC192859.

Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994; 50(4):1088101. https://doi.org/10.2307/2533446. PMid: 7786990.

Egger M, Davey SG, Schneider M, Minder C. Bias in metaanalysis detected by a simple, graphical test. BMJ. 1997; 315(7109):629-34. https://doi.org/10.1136/bmj.315.7109.629. PMid: 9310563, PMCid: PMC2127453.

Chang HW, Chan A, Kwong DLW, Wei WI, Sham JST, Yuen APW. Evaluation of Hypermethylated tumor suppressor genes as tumor markers in mouth and throat rinsing fluid, nasopharyngeal swab and peripheral blood of nasopharygeal carcinoma patient. Int. J. Cancer. 2003; 105:851-55. https://doi.org/10.1002/ijc.11162. PMid: 12767073.

Wong TS, Tang KC, Kwong DLW, Sham JST, Wei WI, Kwong YL, et al. Differential gene methylation in undifferentiated nasopharyngeal carcinoma. International Journal of Oncology. 2003; 22:869-74. https://doi.org/10.3892/ijo.22.4.869.

Tsao SW, Liu Y, Wang XX, Yuen PW, Leung SY, Yuen ST, et al. The association of E-cadherin expression and the methylation status of the E-cadherin gene in nasopharyngeal carcinoma cells. European Journal of Cancer. 2003; 39:524-31. https://doi.org/10.1016/S0959-8049(02)00494-X.

Li Z, Lin SX, Liang YJ. Influence of E-cadherin promoter methylation and mutation of beta-catenin on invasion and metastasis of nasopharyngeal carcinoma cells. Europe PMC. 2003; 25(3):238-42.

Li Z, Lin S, Liang YJ. Detection of gene promoter methylation and mRNA, protein expression levels of E-cadherin in nasopharyngeal carcinoma. Springer. 2003; 32(1):25.30. PMID:12760799

Wong TS, Kwong DLW, Sham JST, Wei WI, Kwong YL, Yuen APW. Quantitative plasma hypermethylated DNA markers of undifferentiated nasopharyngeal carcinoma. Clinical Cancer Research. 2004; 10:2401-06. https://doi.org/10.1158/10780432.CCR-03-0139. PMid: 15073117.

Li Z, Ren Y, Lin SX, Liang YJ, Liang HZ. Association of E-cadherin and beta-catenin with metastasis in nasopharyngeal carcinoma. Europe PMC. 2004; 117(8):1232-39.

Tan SH, Ida H, Goh BC, Hsieh W, Loh M, Ito Y. Analyses of promoter hypermethylation for RUNX3 and other tumor suppressor genes in nasopharyngeal carcinoma. Anticancer Research. 2006; 26:4287-92.

Niemhom S, Kitazawa S, Kitazawa R, Maeda S, Leopairat J. Hypermethylation of epithelial-cadherin gene promoter is associated with Epstein-Barr virus in nasopharyngeal carcinoma. Cancer Detection and Prevention. 2008; 32:127-34. https://doi.org/10.1016/j.cdp.2008.05.005. PMid:18632221.

Ayadi W, Karray-Hakim H, Khabir A, Feki L, Charfi S, Boudawara T, et al. Aberrant methylation of p16, DLEC1, BLU and E-Cadherin gene promoters in nasopharyngeal carcinoma biopsies from tunisian patients. Anticancer Research. 2008; 28:2161-68.

Ran Y, Wu S, You Y. Demethylation of E-cadherin gene in nasopharyngeal carcinoma could serve as a potential therapeutic strategy. J. Biochem. 2011; 149(1):49-54. https://doi.org/10.1093/jb/mvq128.PMid: 21059597.

Challouf S, Ziadi S, Zaghdoudi R, Ksiaa F, Ben Gacem R, Trimeche M. Patterns of aberrant DNA hypermethylation in nasopharyngeal carcinoma in Tunisian patients. Clinica. Chimica. Acta. 2012; 413:795-802. https://doi.org/10.1016/j.cca.2012.01.018. PMid: 22296674.

Li LL, Shu XS, Wang ZH, Cao Y, Tao Q. Epigenetic disruption of cell signaling in nasopharyngeal carcinoma. Chin. J. Cancer. 2011; 30(4):231-39. https://doi.org/10.5732/cjc.011.10080 PMid: 21439244, PMCid: PMC4013349.

Jiang W, Cai R, Chen QQ. DNA Methylation biomarkers for nasopharyngeal carcinoma: Diagnostic and prognostic tools. Asian Pac. J. Cancer Prev. 2015; 16(18):8059-65. https://doi.org/10.7314/APJCP.2015.16.18.8059. PMid: 26745039.

Semb H, Christofori G. The tumor-suppressor functions of E-cadherin. Am. J. Hum. Genet. 1998; 63(6):1588-93. https://doi.org/10.1086/302173. PMid: 9837810, PMCid: PMC1377629.

Pećina-Slaus N. Tumor suppressor gene E-cadherin and its role in normal and malignant cells. Cancer Cell Int. 2003; 3(1):17. https://doi.org/10.1186/1475-2867-3-17 PMid: 14613514, PMCid: PMC270068.

Huang Z, Bassil CF, Murphy SK. Methylation-specific PCR. Methods Mol. Biol. 2013; 1049:75-82. https://doi.org/10.1007/978-1-62703-547-7_7. PMid: 23913210.

Agodi A, Barchitta M, Quattrocchi A, Maugeri A, Vinciguerra M. DAPK1 promoter Methylation and cervical cancer risk: A systematic review and a meta-analysis. PLoS One. 2015; 10(8):e0135078. https:// doi.org/10.1371/journal.pone.0135078. PMid: 26267895, PMCid: PMC4534406.

Username
Password
Remember me